News | November 01, 2022
Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Subscribe To Our Newsletter & Stay Updated
